Palbociclib (PD-0332991) HCl

For research use only.

Licensed by Pfizer Catalog No.S1116

201 publications

Palbociclib (PD-0332991) HCl Chemical Structure

Molecular Weight(MW): 483.99

Palbociclib (PD-0332991) HCl is a highly selective inhibitor of CDK4/6 with IC50 of 11 nM/16 nM in cell-free assays, respectively. It shows no activity against CDK1/2/5, EGFR, FGFR, PDGFR, InsR, etc. Phase 3.

Size Price Stock Quantity  
EUR 108 In stock
EUR 167 In stock
EUR 560 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Selleck's Palbociclib (PD-0332991) HCl has been cited by 201 publications

Purity & Quality Control

Choose Selective CDK Inhibitors

Biological Activity

Description Palbociclib (PD-0332991) HCl is a highly selective inhibitor of CDK4/6 with IC50 of 11 nM/16 nM in cell-free assays, respectively. It shows no activity against CDK1/2/5, EGFR, FGFR, PDGFR, InsR, etc. Phase 3.
Features Non-cytotoxic, and halts cancer cell growth & could be used in glioblastoma that has relapsed after temozolomide treatment (a chemotherapeutic used to treat many cancers).
Targets
CDK4/CyclinD3 [1]
(Cell-free assay)
CDK4/CyclinD1 [1]
(Cell-free assay)
CDK6/CyclinD2 [1]
(Cell-free assay)
9 nM 11 nM 15 nM
In vitro

PD 0332991 has little effect on other protein kinases including EGFR, FGFR, PGFR, IR. PD 0332991 is a non-ATP competitive inhibitor of Cdk4. PD 0332991 inhibits MDA-MB-435 breast carcinoma cells with IC50 of 66 nM, which is due to reduced Rb phosphorylation at Ser780. PD 0332991 inhibits thymidine incorporation into the DNA of Rb-positive human breast, colon, and lung carcinomas as well as human leukemias, with IC50 values ranging from 0.04-0.17 μM. PD 0332991 shows no activity in Rb-negative cells. PD 0332991 causes an accumulation of cells in G1 in MDA-MB-453 breast and Colo-205 carcinoma cells. [1] PD 0332991 also shows activity in 5T33MM myeloma cells (immunocompetent model) and sensitizes the cells to killing by bortezomib. [2] PD 0332991 inhibits luminal ER-positive as well as HER2-amplified breast cancer cell lines including MDA-MB-175, ZR-75-30, CAMA-1, MDA-MB-134, HCC-202 and UACC-893. PD 0332991 enhances the activity of tamoxifen and trastuzumab in these cell lines. PD 0332991 enhances the sensitivity of tamoxifen in the MCF7 tamoxifen-resistant cells. [3] A recent study shows that PD 0332991 could suppress malignant rhabdoid tumor (MRT) cell lines including MP-MRT-AN, KP-MRT-RY, G401, KP-MRT-NS and the sensitivity of the MRT cell lines to PD 0332991 is inversely correlated with expression of p16. [4]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
MOLM13 M136O2tqdmG|ZTDBd5NigQ>? NEDZd48zPCCq M2S3TmlvcGmkaYTpc44hd2ZiQ1TLOEBie3Onc4Pl[EBieyCrbnjpZol1cW:wIH;mJHJjKHCqb4PwbI9zgWyjdHnvckB4cXSqIFnDOVAhd2ZiMD6wNFIh|ryP NICxVZMzPDZ2MUGwNy=>
COLO205 NIXsfpNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEO2c284OiCq M2rG[2FvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIF{e2W|c3XkJIF{KGmwY3;ydI9z[XSrb36gc4YhYzOKXYTofY1q\GmwZTDpcpRwKESQQTD3bZRpKEmFNUCgc4YhOC5yM{[g{txO MV6yOFY1OTFyMx?=
U937 MkjFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MV23NkBp NYHLcWxISW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[XO|ZYPz[YQh[XNiaX7jc5Jxd3KjdHnvckBw\iCdM1jdeIh6dWmmaX7lJIlvfG9iRF7BJJdqfGhiSVO1NEBw\iByLkG0JO69VQ>? NVXKepl6OjR4NEGxNFM>
MOLM13 NUPlUXlJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NX3Ed2c{PzJiaB?= M{D6NGFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iTV;MUVE{KGOnbHzzJIhiemKxcnnu[{BHVFR|IFnUSEBufXSjboSgZZN{\XO|ZXSgZZMhcW6lb4Lwc5JifGmxbjDv[kBcO0ifdHj5cYllcW6nIHnueI8hTE6DIIfpeIghUUN3MDDv[kAxNjB7NjFOwG0> M{Pjd|I1PjRzMUCz
MOLM13 M2nJSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mny0O|IhcA>? MV\BcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IIPvdoFn\W6rYj3y[ZNqe3SjboSgbJVu[W5iTV;MUVE{KGOnbHzzJIF{e2W|c3XkJIF{KGmwY3;ydI9z[XSrb36gc4YhYzOKXYTofY1q\GmwZTDpcpRwKESQQTD3bZRpKEmFNUCgc4YhOC5yOU[g{txO M2fNUVI1PjRzMUCz
MDA-MB-435 MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWeyOEBp MlvKTWM2OD1yLkG2JO69VQ>? MlzmNVU5ODF6M{G=
K562 NF6yfHlEgXSxdH;4bYMhSXO|YYm= MmD4PVYhcA>? MknDSG1UVw>? M3jsZ2lEPTB;MjFOwG0> NX;1NI4zOjR2MUe1OlY>
DU145 MVvDfZRwfG:6aXOgRZN{[Xl? NXntToNOQTZiaB?= MljkSG1UVw>? NGTiN2JKSzVyPUeuOUDPxE1? M1vXZlI1PDF5NU[2
MDA-MB-231 M3jE[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFLWXFYyKM7:TR?= MkDDNlQhcA>? NEfBOI5FVVOR NFzUOHBE\WyuIHP5Z4xmKGG{cnXzeEBie3Onc4Pl[EBieyCjY3P1cZVt[XSrb36gZZQhTzFicHjhd4U> NV\DS4FmOjR2MUe1OlY>
MCF7 MlL6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHyzV5MyKM7:TR?= NYPXOHBXOjRiaB?= MnvZSG1UVw>? MV3D[YxtKGO7Y3zlJIFzemW|dDDhd5Nme3OnZDDhd{Bi[2O3bYXsZZRqd25iYYSgS|EheGijc3W= NWn5N4duOjR2MUe1OlY>
MCF7 Ml\mT4lv[XOnIFHzd4F6 M1zGelUh|ryP NIr1ZpkzPCCq MVzEUXNQ NF;kS49KdmirYnn0bY9vKG:oIILlZ49u[mmwYX70JGNFUzRxY4njcIlvTDFiYYPz[ZN{\WRiYYOgbY5pcWKrdHnvckBw\iC{ZYTpco9jdGG|dH;tZUBxcG:|cHjvdplt[XSrb36gZZQhW2W{N{iw M{H3d|I1PDF5NU[2
MDA-MB-231 NF;hSlBMcW6jc3WgRZN{[Xl? M{\tNVUh|ryP NEH3O5YzPCCq M4P2O2ROW09? NGC3OpBKdmirYnn0bY9vKG:oIILlZ49u[mmwYX70JGNFUzRxY4njcIlvTDFiYYPz[ZN{\WRiYYOgbY5pcWKrdHnvckBw\iC{ZYTpco9jdGG|dH;tZUBxcG:|cHjvdplt[XSrb36gZZQhW2W{N{iw NXzzXIhEOjR2MUe1OlY>
MDA-MB-231 M13ob2Z2dmO2aX;uJGF{e2G7 M4PIPFEuOTBizszN NIr6doIzPCCq M37VW2ROW09? MnHS[I9meyCwb4SgbY5lfWOnIHHwc5B1d3OrczDhd5Nme3OnZDDhd{BRSVKSIHPs[YF3[Wen NIi5dVMzPDRzN{W2Oi=>
MCF7 NXHyWJh4TnWwY4Tpc44hSXO|YYm= NFTiZmIyNTFyIN88US=> MXWyOEBp M32yOGROW09? MYfkc4V{KG6xdDDpcoR2[2ViYYDvdJRwe2m|IHHzd4V{e2WmIHHzJHBCWlBiY3zlZZZi\2V? M1H3SVI1PDF5NU[2
MDA-MB-231 MWrGeY5kfGmxbjDBd5NigQ>? MUSwMlUuOSEQvF2= NXXvS3JJPDhiaB?= MoXoSG1UVw>? NVvrV|lRcGG|IH7vJGNmdGxiY4njcIUh[XK{ZYP0JIF{e2W|c3XkJIF{KGGlY4XteYxifGmxbjDheEB{fWJvR{GgdIhie2V? MXGyOFQyPzV4Nh?=
MCF7 MoWzSpVv[3Srb36gRZN{[Xl? NYTtZXB5OC53LUGg{txO NXu1U4FxPDhiaB?= NHTJblVFVVOR NETrb25p[XNibn:gR4VtdCCleXPs[UBienKnc4SgZZN{\XO|ZXSgZZMh[WOldX31cIF1cW:wIHH0JJN2[i2JMTDwbIF{\Q>? Mk\mNlQ1OTd3Nk[=
697 Ml7nS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIrqcZVKSzVyPUG0PE4{QCCwTR?= M2\oZnNCVkeHUh?=
P12-ICHIKAWA NFu3enlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGPCUlRKSzVyPUm2MlA1KG6P M2rVNXNCVkeHUh?=
NB69 MnLlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVrJR|UxRTF4MT64JI5O M3jJPXNCVkeHUh?=
EoL-1 MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{faZ2lEPTB;MUi3MlI3KG6P NVjZNI1bW0GQR1XS
BHT-101 M4fIRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYfSTFFoUUN3ME2xPVgvOjVibl2= MmDEV2FPT0WU
SK-NEP-1 MlW4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWD6UJlOUUN3ME2yNlAvODJibl2= NInWb5ZUSU6JRWK=
MHH-NB-11 NHTLSHBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVzJR|UxRTJ{MD6xPUBvVQ>? M2KzN3NCVkeHUh?=
AsPC-1 MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIXwTJdKSzVyPUK1Nk42OyCwTR?= NW\4e5dvW0GQR1XS
ES1 M2Xib2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoO5TWM2OD1{NU[uNlUhdk1? NGL0U|RUSU6JRWK=
LAMA-84 NEjhVW1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVnJR|UxRTJ3OD6xPUBvVQ>? MVjTRW5ITVJ?
MOLT-16 NWD3XoZ[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NETubWJKSzVyPUK1PE41QSCwTR?= NUCyXHhCW0GQR1XS
ES7 NUDQdIRuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MV;JR|UxRTJ5Mz6wPUBvVQ>? MXPTRW5ITVJ?
KY821 MmnpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEDL[ohKSzVyPUOxOE4yKG6P M{OzXXNCVkeHUh?=
RT-112 Ml7IS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVvJR|UxRTN{MT6wOUBvVQ>? MlTUV2FPT0WU
HL-60 MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIXTZZVKSzVyPUO0NE43PiCwTR?= MVfTRW5ITVJ?
MOLT-4 MnjHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVzHeG5lUUN3ME2zOFUvOTNibl2= Mk\pV2FPT0WU
KARPAS-45 MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWTNV|lSUUN3ME2zO|YvOTZibl2= MUTTRW5ITVJ?
SK-N-AS NV\kfI5GT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NH7kcoNKSzVyPUO4O{45OyCwTR?= MWjTRW5ITVJ?
CTB-1 NVzofJd5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIG4Z4pKSzVyPUSwOU4xOiCwTR?= NYXVTolOW0GQR1XS
NKM-1 MoGwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkL1TWM2OD12MUGuPFkhdk1? MVjTRW5ITVJ?
HTC-C3 MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUPJR|UxRTR|Mj65OUBvVQ>? M{TMcXNCVkeHUh?=
BE-13 MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEnXXmlKSzVyPUS0OE4zPyCwTR?= M2fOOnNCVkeHUh?=
KOSC-2 MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MU\JR|UxRTR4Nj65JI5O M3PpRXNCVkeHUh?=
NB14 MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NF;tWpJKSzVyPUS4N{42QCCwTR?= MmDQV2FPT0WU
CAL-27 NETCdnlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWDJR|UxRTR7ND61PUBvVQ>? MYnTRW5ITVJ?
H9 MnHFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlOzTWM2OD12OUWuOFMhdk1? NG[5N5VUSU6JRWK=
RS4-11 MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmT2TWM2OD13MESuO|Mhdk1? MVfTRW5ITVJ?
PA-1 M33tZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkXWTWM2OD13MEmuPFYhdk1? M1LpUXNCVkeHUh?=
MV-4-11 MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEPBWllKSzVyPUWxN{45PSCwTR?= NFHCbVNUSU6JRWK=
OS-RC-2 NVKyUXZ5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUXXXlZoUUN3ME21NlEvPjJibl2= M3LFPXNCVkeHUh?=
RPMI-8226 NHOwbY9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3X4eWlEPTB;NUK2Mlg3KG6P M1uzPHNCVkeHUh?=
HGC-27 NUfmW2ZMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NELLXpNKSzVyPUW2OE46QSCwTR?= M4PMR3NCVkeHUh?=
CHP-212 MnHCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHPDfm9KSzVyPUW5N{42QSCwTR?= NI\FXXZUSU6JRWK=
NB10 NEfYcFFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NV7YOlFCUUN3ME21PVkvOThibl2= M1u1cXNCVkeHUh?=
HH Mny5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXTJR|UxRTV7OT60N{BvVQ>? MlfaV2FPT0WU
EW-16 MoTLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MonaTWM2OD14MEOuOVIhdk1? NXe4UpRbW0GQR1XS
ES8 MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWTlUpVWUUN3ME22NFUvOjFibl2= M1XY[3NCVkeHUh?=
HAL-01 MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MW\JR|UxRTZyNT62O{BvVQ>? M4LZOXNCVkeHUh?=
A204 MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NH\l[oNKSzVyPU[zN{46OSCwTR?= MkfjV2FPT0WU
MHH-PREB-1 M2XEXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4L1NGlEPTB;NkO2Mlk6KG6P NHfvVldUSU6JRWK=
EM-2 MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkfOTWM2OD14NUCuOlQhdk1? MX3TRW5ITVJ?
BV-173 NUTM[|QyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NV3kR2xKUUN3ME22OVIvPDhibl2= NXW5dnNUW0GQR1XS
ONS-76 NETFSYVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFj1PHVKSzVyPU[3O{45OiCwTR?= NHHXOYpUSU6JRWK=
KM-H2 MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVLJR|UxRTZ7NT61OEBvVQ>? Mo\tV2FPT0WU
D-263MG Mo[3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3fmV2lEPTB;N{G3MlEzKG6P MoX5V2FPT0WU
ES3 M17lb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MofaTWM2OD15MkiuPVMhdk1? MWDTRW5ITVJ?
VA-ES-BJ M1LaOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVznb3RbUUN3ME23N|IvOjdibl2= NWLDbZJOW0GQR1XS
NBsusSR NUHhWW5mT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYe0eXBtUUN3ME23OFIvQTlibl2= M17KXHNCVkeHUh?=
NCI-H520 NVTtWY9wT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3W4XGlEPTB;N{S2MlUzKG6P M3j3SHNCVkeHUh?=
ES5 MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFvGOXBKSzVyPUe1Nk45KG6P NF:2ZnNUSU6JRWK=
T-24 NGfLSphIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mmn2TWM2OD15N{iuO|Ehdk1? M4nWPXNCVkeHUh?=
SW962 M4HyXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHPrbIRKSzVyPUiwPE43OyCwTR?= M1uwTnNCVkeHUh?=
EW-3 MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3nXUWlEPTB;OEC4Mlc3KG6P NULWO2tOW0GQR1XS
RXF393 M4TnSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWfZO4poUUN3ME24NVIvPzlibl2= MYHTRW5ITVJ?
U251 NYX1[pd5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlzyTWM2OD16MUOuPFghdk1? MorJV2FPT0WU
CAMA-1 NX3aWY8xT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NITZS3RKSzVyPUizN{46PCCwTR?= MYfTRW5ITVJ?
JVM-3 NHfGRYRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWrJR|UxRTh3MT63PEBvVQ>? MnPXV2FPT0WU
COLO-800 NGLQOFFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYrJR|UxRTh7Nz63PEBvVQ>? Mk[1V2FPT0WU
OVCAR-5 MkLqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYnJR|UxRTlyMD6xJI5O MmPmV2FPT0WU
LB1047-RCC NVjTeWdoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYXyVHR5UUN3ME25NlcvPTZibl2= Mm[wV2FPT0WU
SW954 NVzoXG1iT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWD4NZZHUUN3ME25NlkvPDFibl2= NVv2eFE6W0GQR1XS
J-RT3-T3-5 M2rlWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmPsTWM2OD17M{[uNFYhdk1? NF7LZZdUSU6JRWK=
Mewo MmK0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3;nfmlEPTB;OUO2MlYhdk1? Mm\vV2FPT0WU
NCI-H1770 NEDBWplIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M162WmlEPTB;OUSwMlU2KG6P MUXTRW5ITVJ?
HO-1-N-1 MmnoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFLG[lFKSzVyPUm2Nk45OSCwTR?= NVLWbVNmW0GQR1XS
HSC-3 NXjR[VdVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MULJR|UxRTl4Nj60PEBvVQ>? MVXTRW5ITVJ?
TYK-nu M1O3R2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVXITXljUUN3ME25PVgvOjVibl2= NXnrb4J5W0GQR1XS
KYSE-150 NIjFR|NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4f6RWlEPTB;MT6wNFA4PiEQvF2= NYroeXRJW0GQR1XS
SN12C Mnz5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWLFToR7UUN3ME2xMlAxQDd3IN88US=> MXnTRW5ITVJ?
MOLT-13 MlfuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoHkTWM2OD1zLkCxOFIyKM7:TR?= Mnq5V2FPT0WU
TE-11 MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4HOfGlEPTB;MT6wOFgyOiEQvF2= MX3TRW5ITVJ?
DB M163c2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFTQeYRKSzVyPUGuNFczPzNizszN NXXONXRUW0GQR1XS
CAL-39 NHGyUI1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHXVcZdKSzVyPUGuNFc2OjJizszN MWLTRW5ITVJ?
A3-KAW NEHIfZBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWe0d2xpUUN3ME2xMlA5PDB6IN88US=> Mn3TV2FPT0WU
CHP-134 MmjMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlTxTWM2OD1zLkGxPFA4KM7:TR?= MVTTRW5ITVJ?
TGW MlfJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlzmTWM2OD1zLkGyN|k2KM7:TR?= Mmm2V2FPT0WU
QIMR-WIL MoLFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFjRS3ZKSzVyPUGuNVMyOzRizszN Mln1V2FPT0WU
NCI-SNU-1 NXK1OVlZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYfkbY5SUUN3ME2xMlE3OzV2IN88US=> MmCzV2FPT0WU
CGTH-W-1 NFfEbmxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1KxZWlEPTB;MT6xO|E5PiEQvF2= NWLpUI1xW0GQR1XS
MHH-ES-1 MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkXOTWM2OD1zLkG3PVg3KM7:TR?= NWS1ZY0xW0GQR1XS
LB2241-RCC NIHXdoJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGm3R|lKSzVyPUGuNVg3OiEQvF2= NGLzRmdUSU6JRWK=
ML-2 MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWS2VnhvUUN3ME2xMlIxPzN2IN88US=> MXvTRW5ITVJ?
COR-L23 NX\XR3V3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NF\tbHBKSzVyPUGuNlI6OzNizszN MmDPV2FPT0WU
BFTC-905 NWPLW2xET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmT5TWM2OD1zLkK0NlY4KM7:TR?= NH\XemVUSU6JRWK=
Hs-578-T M{m1[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{OyOGlEPTB;MT6yOVgyPyEQvF2= NVzUW3BoW0GQR1XS
KG-1 MlLDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M33DRWlEPTB;MT6yOlY5PiEQvF2= NXK4PG5KW0GQR1XS
HEL MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVnJR|UxRTFwMkmzN|gh|ryP MU\TRW5ITVJ?
A549 MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MU\JR|UxRTFwMkmzPVkh|ryP NFPWcYNUSU6JRWK=
COLO-741 MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVLJR|UxRTFwM{KwPFkh|ryP MmryV2FPT0WU
PC-3 MmHjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVLJR|UxRTFwM{WyNlEh|ryP M13oVXNCVkeHUh?=
HOS MnjaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVLJR|UxRTFwM{WyPVYh|ryP NWjYO2ZZW0GQR1XS
HT-1080 MojES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{OyUWlEPTB;MT6zO|UyQSEQvF2= MY\TRW5ITVJ?
TE-8 M4W5UGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEjLR2dKSzVyPUGuOFE4PzRizszN MYnTRW5ITVJ?
BHY M1r0VWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M33TTmlEPTB;MT60OlkzOyEQvF2= M{Pn[3NCVkeHUh?=
BB65-RCC MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2jTV2lEPTB;MT61NFUzQCEQvF2= NFO1eFRUSU6JRWK=
HN MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MULJR|UxRTFwNUSwO|Eh|ryP MnfYV2FPT0WU
NCI-H441 MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGDieWFKSzVyPUGuOVQ6ODdizszN MYPTRW5ITVJ?
RPMI-8866 MnzMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXXJR|UxRTFwNUi1NFch|ryP NWj4V4duW0GQR1XS
CAL-62 MofRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUXoNpRLUUN3ME2xMlYxQDZ{IN88US=> NUe1XGNSW0GQR1XS
MG-63 MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoK5TWM2OD1zLk[xPFE{KM7:TR?= NWexVWxEW0GQR1XS
SK-LU-1 NVzjfmduT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2rKS2lEPTB;MT62NlE2OiEQvF2= MYjTRW5ITVJ?
BCPAP M2jheWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NX;l[ppMUUN3ME2xMlY3PDV5IN88US=> M4npTnNCVkeHUh?=
22RV1 NInZR|FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnS0TWM2OD1zLk[3PFQ{KM7:TR?= M2nxdHNCVkeHUh?=
T47D NXfvOIR4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MX3JR|UxRTFwNkiwOlEh|ryP MmPuV2FPT0WU
MSTO-211H MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEm0TY1KSzVyPUGuOlk3ODNizszN M2DzOHNCVkeHUh?=
DEL Mlu0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NF3NdGFKSzVyPUGuO|AzPzNizszN MkLqV2FPT0WU
H4 MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVzJR|UxRTFwN{OyNVIh|ryP MWnTRW5ITVJ?
CAL-51 MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{PoZmlEPTB;MT63OFg2PSEQvF2= Ml61V2FPT0WU
ABC-1 Mn\FS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGS1[mVKSzVyPUGuO|g2QDJizszN M1:4bXNCVkeHUh?=
MZ2-MEL M{Thb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3XTUmlEPTB;MT63PVU1OiEQvF2= NX;zdFlWW0GQR1XS
YKG-1 NVnJUlVNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXHJR|UxRTFwOEGwOlEh|ryP MljUV2FPT0WU
KM12 M4X2PWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3rpUGlEPTB;MT64NVYxOiEQvF2= M1G2XnNCVkeHUh?=
L-363 M1vafmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXvJR|UxRTFwOEe0NVIh|ryP MVrTRW5ITVJ?
KU812 M2T6Tmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mn\HTWM2OD1zLki5NlgzKM7:TR?= NWDZUolMW0GQR1XS
LOXIMVI Mn6xS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHHKVmJKSzVyPUGuPVEzOjhizszN NIfFO|NUSU6JRWK=
G-401 NXu0SFRvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVjpbHZiUUN3ME2xMlkzPDJ6IN88US=> MVrTRW5ITVJ?
SW780 NVzOcWtMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXLlfZhpUUN3ME2xMlk3OjR4IN88US=> MkP4V2FPT0WU
SW872 NGDCO3BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHXGUG5KSzVyPUGuPVg{OyEQvF2= NXS1enJuW0GQR1XS
NB7 NITDVpNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYHJR|UxRTFwOUmzNlMh|ryP MmfHV2FPT0WU
T98G MmjuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1HBVWlEPTB;Mj6wNFY3PiEQvF2= NFnC[FlUSU6JRWK=
SW1710 MmPSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGXjepJKSzVyPUKuNFY6PDVizszN MlixV2FPT0WU
NCI-H1573 MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWLJR|UxRTJwMEeyPVgh|ryP MWfTRW5ITVJ?
KE-37 NIHYZmVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2fDWGlEPTB;Mj6wPFk2OSEQvF2= NGmyellUSU6JRWK=
786-0 M4rGbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGX1NXFKSzVyPUKuNVU1OzlizszN Mnf1V2FPT0WU
SAS NFL2N4RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWTJR|UxRTJwMkCzO|Qh|ryP M1\zZnNCVkeHUh?=
CAL-54 M3LqVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFXrZVZKSzVyPUKuNlA1OTNizszN MYXTRW5ITVJ?
SF268 MmexS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWTJR|UxRTJwMkOxNlIh|ryP NULJSZF[W0GQR1XS
SW620 M4f6SWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1rzdWlEPTB;Mj6yOlE3QSEQvF2= NHPUfIhUSU6JRWK=
MN-60 NHLYdWZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEW0VW1KSzVyPUKuN|ExPiEQvF2= M3Hj[3NCVkeHUh?=
EFO-27 NYnDN4ZlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlzMTWM2OD1{LkOyNFU5KM7:TR?= MXrTRW5ITVJ?
NCI-H747 M3;M[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoiwTWM2OD1{LkOyNVk6KM7:TR?= NYm0RXNnW0GQR1XS
HCC2218 NIfCVXdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2P5RmlEPTB;Mj6zOVM4PCEQvF2= MoXQV2FPT0WU
MIA-PaCa-2 NYDnO5VTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVTJR|UxRTJwM{[0N|ch|ryP MlzzV2FPT0WU
SJSA-1 MkXCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGrsO|ZKSzVyPUKuN|c4QTZizszN MWPTRW5ITVJ?
RKO Mmn2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2XV[2lEPTB;Mj6zPFQ6PiEQvF2= MUDTRW5ITVJ?
NB6 NVjWd4E5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmXxTWM2OD1{LkSwN|c1KM7:TR?= MYnTRW5ITVJ?
ES4 MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NILzWllKSzVyPUKuOFU1OjJizszN NFzBfoZUSU6JRWK=
EGI-1 NH;hfmdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUPJR|UxRTJwNE[4PFMh|ryP MkfKV2FPT0WU
CTV-1 NGTrcoJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3zHbmlEPTB;Mj61Nlc4OyEQvF2= M4e0WHNCVkeHUh?=
NCI-H1355 MlzOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NY\MSW9UUUN3ME2yMlU2QTVzIN88US=> NFnIdVNUSU6JRWK=
GT3TKB MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn;xTWM2OD1{LkW5NVk6KM7:TR?= NXPCfmJMW0GQR1XS
SK-HEP-1 MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUfJR|UxRTJwNUmyOlYh|ryP NHPvUG9USU6JRWK=
GAMG NGK5SZhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4DxSGlEPTB;Mj61PVM6PCEQvF2= NWrsOFJ7W0GQR1XS
SK-MES-1 MoWxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4PhT2lEPTB;Mj62NVgxOyEQvF2= MWHTRW5ITVJ?
RO82-W-1 NFnHcY1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3\oe2lEPTB;Mj62NlA2PyEQvF2= NEPNb3ZUSU6JRWK=
ECC10 MlfvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXfQcm84UUN3ME2yMlcxOjB4IN88US=> NX;mbJFHW0GQR1XS
MCF7 NGDEd3lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkfRTWM2OD1{LkexOFY1KM7:TR?= NHjn[WpUSU6JRWK=
D-283MED Mn\rS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkPOTWM2OD1{LkeyOFMh|ryP Mk\YV2FPT0WU
RPMI-7951 M4G3Nmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{LHeGlEPTB;Mj63OVY6PCEQvF2= M1rHSHNCVkeHUh?=
Ramos-2G6-4C10 NUO0T2dST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4HoSWlEPTB;Mj63O|A6QSEQvF2= M2[wU3NCVkeHUh?=
KGN M{nzPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFPkS5BKSzVyPUKuPFE5QDRizszN NH3MeXFUSU6JRWK=
NUGC-3 NWXwbnp[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGfBWHFKSzVyPUKuPFI2ODVizszN M2PUTXNCVkeHUh?=
NCI-H292 NUX0S5RpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGLZeplKSzVyPUKuPFUxPTNizszN NUHGTYN5W0GQR1XS
Becker MkS3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NH\mcGtKSzVyPUKuPVU5OzJizszN NYC2cGhLW0GQR1XS
NCI-H1299 Mk\5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWjJR|UxRTNwMEWyOlMh|ryP NWPTbnA4W0GQR1XS
ETK-1 M3\WO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWT4WXppUUN3ME2zMlA2PDNizszN M{m0UXNCVkeHUh?=
TK10 MlfJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4rLOGlEPTB;Mz6yNFE3PSEQvF2= MnflV2FPT0WU
VMRC-RCZ MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVLqOnVPUUN3ME2zMlM3PDh6IN88US=> MkH0V2FPT0WU
YH-13 MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWXOfJVwUUN3ME2zMlQ1ODd7IN88US=> NH;NZ5VUSU6JRWK=
DU-145 NHqxbVlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mkj1TWM2OD1|LkS2NlY6KM7:TR?= MormV2FPT0WU
SW1088 MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4jaT2lEPTB;Mz60O|Q4KM7:TR?= M{n6eHNCVkeHUh?=
HOP-92 NGPqSHVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mm\tTWM2OD1|LkWwN|QzKM7:TR?= MWTTRW5ITVJ?
KP-N-YS NUS4W2Q6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M13NTGlEPTB;Mz62NlE{QSEQvF2= NXLzfo1DW0GQR1XS
NCI-H460 M4\FR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2raRWlEPTB;Mz62Olc{KM7:TR?= NUnvSWp2W0GQR1XS
U-2-OS M1fNeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NV;KS|d4UUN3ME2zMlczPTN3IN88US=> MkXXV2FPT0WU
A101D M4riWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXLJR|UxRTNwN{[5N|Yh|ryP NVe3OXZuW0GQR1XS
MDA-MB-231 MoHIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2LWbGlEPTB;Mz64NVk2OSEQvF2= MYLTRW5ITVJ?
IST-MES1 NYLpSnE6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NH3xVpNKSzVyPUOuPFMzKM7:TR?= NYHRO5dzW0GQR1XS
COR-L105 MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVPJR|UxRTRwMEG4JO69VQ>? MVnTRW5ITVJ?
NCI-H1437 MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYjJR|UxRTRwMEKzNFIh|ryP MoTOV2FPT0WU
CAL-85-1 MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mli0TWM2OD12LkCyOFYyKM7:TR?= MWPTRW5ITVJ?
MZ1-PC NIC4SnFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmHMTWM2OD12LkG4OVU3KM7:TR?= MlPDV2FPT0WU
VM-CUB-1 MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnrwTWM2OD12LkOxNlg1KM7:TR?= Mn\YV2FPT0WU
CHL-1 MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnXHTWM2OD12LkOyNVY6KM7:TR?= NIXLNXFUSU6JRWK=
MDA-MB-361 M2PaPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NU[3W4xMUUN3ME20MlM{OTV|IN88US=> NYPqbnY2W0GQR1XS
NCI-H661 NHLPTlFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M13ETmlEPTB;ND61NFA6OiEQvF2= M2j5[nNCVkeHUh?=
EW-11 Mmf5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MX;JR|UxRTRwNUKyN|Eh|ryP NED3[HRUSU6JRWK=
BEN MkfnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnHqTWM2OD12LkWyPFE2KM7:TR?= NVziUpVQW0GQR1XS
BFTC-909 M4fBWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2\ZeGlEPTB;ND61OlI4PSEQvF2= MUPTRW5ITVJ?
NCI-H2087 MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmnLTWM2OD12LkW4NVY1KM7:TR?= NF;Qb5hUSU6JRWK=
RVH-421 NHHFbnNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3TEPWlEPTB;ND62OlY6KM7:TR?= NV3PWpMxW0GQR1XS
P30-OHK MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NE[xVVlKSzVyPUSuOlgxODhizszN NWHNeoRiW0GQR1XS
NCI-H28 M2HnXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIf6Z5lKSzVyPUSuPFE3PjFizszN NWnMWY5JW0GQR1XS
ES6 MmroS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmDqTWM2OD12LkizNFE3KM7:TR?= MnjzV2FPT0WU
769-P NYj0Onh6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoDqTWM2OD12Lki1PVI3KM7:TR?= M2fOV3NCVkeHUh?=
OE33 MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWDJR|UxRTRwOEixOlEh|ryP M{DTb3NCVkeHUh?=
SW982 NXXrSWN5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVPJR|UxRTRwOUWwOlEh|ryP NUj2bWozW0GQR1XS
A388 NVHwRldUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M13KZ2lEPTB;NT6wNlk5OyEQvF2= NVy2b3dnW0GQR1XS
TI-73 NF;qb5RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1rZ[2lEPTB;NT6wOlE6PCEQvF2= MoHJV2FPT0WU
HCT-116 MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mm\jTWM2OD13LkC5PFg6KM7:TR?= NFfEOHFUSU6JRWK=
HuP-T3 MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MV3JR|UxRTVwMUi3NFkh|ryP MmTxV2FPT0WU
G-402 MmPDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NX\5WnlpUUN3ME21MlE6PDF4IN88US=> NWXiTFh4W0GQR1XS
NCI-H1792 NXjwRWlPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2\HXGlEPTB;NT6yOFYzOiEQvF2= NUXucY5ZW0GQR1XS
NCI-H209 MlTMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFO5fYNKSzVyPUWuNlU6PDJizszN MnvOV2FPT0WU
NCI-H1650 MmLJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYTJR|UxRTVwM{C2N|Qh|ryP MUPTRW5ITVJ?
LCLC-97TM1 M{jNSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVTJR|UxRTVwM{G4NFgh|ryP MWDTRW5ITVJ?
S-117 M{LZcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFqyNHhKSzVyPUWuN|Y6PzZizszN M37idHNCVkeHUh?=
GI-ME-N M{LEZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MX\JR|UxRTVwM{m2PFEh|ryP MkXLV2FPT0WU
NCI-H2122 NHnPPYVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnP5TWM2OD13LkS5N|k4KM7:TR?= NF\h[GFUSU6JRWK=
NCI-H1793 NFizZmdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3;lSWlEPTB;NT62O|U6OyEQvF2= NYHuT2NHW0GQR1XS
C2BBe1 MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{jXXWlEPTB;NT63NFA5QCEQvF2= MY\TRW5ITVJ?
TE-12 MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{\mTWlEPTB;NT64NFU2PiEQvF2= NIHadm9USU6JRWK=
LCLC-103H Mk\OS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{TDOWlEPTB;NT65NVch|ryP MWXTRW5ITVJ?
A673 MorHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWjJR|UxRTVwOUG5N|Ih|ryP MmjlV2FPT0WU
BB30-HNC M{DJemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlHmTWM2OD13Lkm4N|Yh|ryP NHGxT|ZUSU6JRWK=
SF295 MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4rM[2lEPTB;Nj6wNFQzOiEQvF2= NXTE[nZbW0GQR1XS
KU-19-19 M{TiZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVHjUFFkUUN3ME22MlAyPzNzIN88US=> NEO1XXFUSU6JRWK=
CFPAC-1 M1;VeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHnwR|hKSzVyPU[uNFQ1PDNizszN NXfvVmdTW0GQR1XS
LoVo NXjMOVNyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnvyTWM2OD14LkC1NFY{KM7:TR?= M4XzfHNCVkeHUh?=
8505C M2\5ZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3jpdGlEPTB;Nj6wO|U4OyEQvF2= M{LROHNCVkeHUh?=
GMS-10 M3;leGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGj1[I9KSzVyPU[uNVUxODJizszN MUnTRW5ITVJ?
Ca9-22 MlnsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NH7aR|BKSzVyPU[uNVY4OSEQvF2= NFrBeXJUSU6JRWK=
DOK NYPGWJhkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NETVNldKSzVyPU[uNlIxPzJizszN M2rEfnNCVkeHUh?=
FADU NFLmfpVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHjTR5RKSzVyPU[uNlYxOzlizszN NUfjfmZYW0GQR1XS
BxPC-3 NHnUeZlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHHmbZlKSzVyPU[uNlc{OiEQvF2= Mn;lV2FPT0WU
CAL-33 MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NV6xSIM3UUN3ME22MlI6OjBzIN88US=> MlLNV2FPT0WU
SHP-77 M1nIfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2X5VWlEPTB;Nj6zNVUyOiEQvF2= MYXTRW5ITVJ?
LXF-289 M4TtVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUfJR|UxRTZwM{O0OVUh|ryP MknpV2FPT0WU
GB-1 NYjOWVJmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlfOTWM2OD14LkO4NkDPxE1? NWrTVXBkW0GQR1XS
KS-1 MkW1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGK0[W5KSzVyPU[uN|g1PDdizszN NH7HSFFUSU6JRWK=
D-502MG M33tZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmLsTWM2OD14LkSyN|c3KM7:TR?= NHOycmRUSU6JRWK=
LAN-6 MnLLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmDlTWM2OD14LkWxNFI{KM7:TR?= MX7TRW5ITVJ?
H-EMC-SS NHXYWndIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHfTZpdKSzVyPU[uOVYyPDdizszN NYGwRWh7W0GQR1XS
LC-2-ad MnzpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{TnNGlEPTB;Nj62NFA4PiEQvF2= M3uxbHNCVkeHUh?=
NCI-H1693 MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnftTWM2OD14Lk[yNlE2KM7:TR?= M3L0NnNCVkeHUh?=
SK-N-FI M1rlbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{jsOGlEPTB;Nj63OVA1PCEQvF2= M3fNS3NCVkeHUh?=
D-423MG M1TUfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mkn5TWM2OD14Lke2NVE4KM7:TR?= MkT1V2FPT0WU
KNS-42 NYnhU4FwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUHJR|UxRTZwN{ixPVch|ryP NWPudXZoW0GQR1XS
GCT MmX6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXXJR|UxRTZwOUO4JO69VQ>? MVPTRW5ITVJ?
DSH1 NH:wT3pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXjJR|UxRTdwME[zN{DPxE1? MXPTRW5ITVJ?
D-247MG MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4\JeGlEPTB;Nz6wO|g5OSEQvF2= MljSV2FPT0WU
NCI-SNU-5 MnrYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIXTbW1KSzVyPUeuNVg{PzFizszN MYDTRW5ITVJ?
TE-6 NYT2doU5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVPJR|UxRTdwMkC2NFEh|ryP MoHnV2FPT0WU
NOMO-1 NFrlNYdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnTJTWM2OD15LkKyNVI4KM7:TR?= M1K1RnNCVkeHUh?=
NB17 MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mmm4TWM2OD15LkOwN|A6KM7:TR?= NIfZXFVUSU6JRWK=
EW-22 MlqzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYXJR|UxRTdwM{SzOFgh|ryP MWTTRW5ITVJ?
EW-13 NWL6cXA3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlK5TWM2OD15LkO1NVYzKM7:TR?= NGTzOZBUSU6JRWK=
DOHH-2 MnLnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFPRTGRKSzVyPUeuOFQxOiEQvF2= MkmyV2FPT0WU
TGBC1TKB MkTLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3\3SWlEPTB;Nz60PVg6QSEQvF2= MmPvV2FPT0WU
GR-ST MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIT0eHRKSzVyPUeuOVI2QTRizszN MUTTRW5ITVJ?
KYSE-520 NWWyeHVYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXXJR|UxRTdwNUW1NVUh|ryP NHi2UpBUSU6JRWK=
CAPAN-1 M2nzemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkX4TWM2OD15LkW5OVEh|ryP M1rsV3NCVkeHUh?=
HCE-4 NILtT|VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYDJR|UxRTdwNkKyO|kh|ryP NXjTWolzW0GQR1XS
MLMA MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NU\EZW5IUUN3ME23MlYzQTV5IN88US=> NVX4XndEW0GQR1XS
HT-144 M1TocWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MX7JR|UxRTdwNkWzOlgh|ryP MXnTRW5ITVJ?
KYSE-180 Mmj0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnLXTWM2OD15LkexNVY6KM7:TR?= NX3JfJlpW0GQR1XS
TE-5 NGDy[FFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUPJR|UxRTdwOUW5O|Eh|ryP MUfTRW5ITVJ?
IGROV-1 NVzofI9HT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFnBNFNKSzVyPUeuPVg2PTFizszN MYXTRW5ITVJ?
NCI-H1581 MnHrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NU\ISW5wUUN3ME24MlAyOiEQvF2= NV;NdpAxW0GQR1XS
SW1990 MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnnFTWM2OD16LkC0OlU6KM7:TR?= NYOxb4NlW0GQR1XS
EFM-19 NUjMWmg{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEn6fo9KSzVyPUiuNFg2PDVizszN NGXMbmVUSU6JRWK=
OGR-1 MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn;rTWM2OD16LkSzNFI{KM7:TR?= M1\0dnNCVkeHUh?=
U-118-MG MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnLiTWM2OD16LkSzOFY{KM7:TR?= M2jaR3NCVkeHUh?=
SK-OV-3 Mkn3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYLaflROUUN3ME24MlQ3PzZ3IN88US=> Mne2V2FPT0WU
KNS-62 MmnoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4OyUGlEPTB;OD61NVc3OSEQvF2= M{H3W3NCVkeHUh?=
GOTO MkniS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2jnRmlEPTB;OD61O|Y{PSEQvF2= MWfTRW5ITVJ?
8305C MmLJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEX0PWRKSzVyPUiuO|A1QDRizszN MnP5V2FPT0WU
RPMI-2650 NHHTeHlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoXsTWM2OD16LkexPVU2KM7:TR?= NEHwRoRUSU6JRWK=
NEC8 NXnQdI5PT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYPwO41zUUN3ME24Mlc1OzB5IN88US=> MYDTRW5ITVJ?
KYSE-450 MnH6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGDocXVKSzVyPUiuPFY2PDhizszN NWjsVIg6W0GQR1XS
RMG-I NVLUW2RWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkfyTWM2OD17LkG0NFU5KM7:TR?= M3LUPXNCVkeHUh?=
CAKI-1 MlXJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2rOeGlEPTB;OT6zNVk4QSEQvF2= NI\kSI1USU6JRWK=
KYSE-510 MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXK0eJkzUUN3ME25MlM2Pzd6IN88US=> Mmi1V2FPT0WU
A4-Fuk MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkL3TWM2OD17LkO2O|AyKM7:TR?= NUjW[mJjW0GQR1XS
AN3-CA M3HKN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmLDTWM2OD17LkS1OFQ1KM7:TR?= NHmz[oxUSU6JRWK=
SK-N-DZ NUiyTGp7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHP5VXFKSzVyPUmuO|I5PDlizszN NEPR[ZZUSU6JRWK=
HSC-2 MmK2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUnFXVIyUUN3ME25Mlc3PjJ7IN88US=> M3W4U3NCVkeHUh?=
EW-1 NVPJT4FsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUC5d3R2UUN3ME25Mlc6OzZ7IN88US=> MlTOV2FPT0WU
D-566MG MkTMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2[5ZWlEPTB;OT64N|Y3PCEQvF2= NXjHTIJUW0GQR1XS
COLO-792 NYXQdo9ZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXfJR|UxRTlwOUi3OFYh|ryP M3[0OnNCVkeHUh?=
TE-10 Mny2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1y0SmlEPTB;MUCuNFM6PiEQvF2= M4K4[3NCVkeHUh?=
NCI-H650 NGHXOXVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGHtdZBKSzVyPUGwMlQzQDZizszN MULTRW5ITVJ?
U-266 MoTLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV\3PZoyUUN3ME2xNE41PTVizszN Mo[yV2FPT0WU
Detroit562 Mom3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWLGeVBJUUN3ME2xNU4xPTF3IN88US=> NXzFNY5jW0GQR1XS
NH-12 NWHJSIlJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3jaZWlEPTB;MUGuNVQ1PiEQvF2= NGHofIlUSU6JRWK=
CO-314 MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2fmUGlEPTB;MUGuNlg1OiEQvF2= NHjmNllUSU6JRWK=
IST-MEL1 NX\xbGNnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3:ydmlEPTB;MUGuOVMzOyEQvF2= NIDmT3dUSU6JRWK=
KNS-81-FD M3rYbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYrJSVdwUUN3ME2xNU42PTJ5IN88US=> M3;CNHNCVkeHUh?=
SW1463 NF7R[5FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWHJR|UxRTFzLkW5PFkh|ryP M2XWWnNCVkeHUh?=
NCI-H23 MkfXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnXyTWM2OD1zMT62OVUzKM7:TR?= NUmwUnk1W0GQR1XS
SK-MEL-2 NFLIeGtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4ix[mlEPTB;MUGuO|E6PyEQvF2= MmDhV2FPT0WU
NB13 NWXkemlWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUHwdYxVUUN3ME2xNk4yPDl3IN88US=> MlPtV2FPT0WU
Daoy NIe1eWdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHzyXnJKSzVyPUGyMlI5PTZizszN NYT3PWpOW0GQR1XS
NCI-H1623 NFnJOJFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NY\MfIVWUUN3ME2xNk4{QDBzIN88US=> NE\uVJhUSU6JRWK=
NMC-G1 NH;0RpJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHf6ZXZKSzVyPUGyMlcyPyEQvF2= MXjTRW5ITVJ?
DK-MG M4rBVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIHVRo5KSzVyPUGyMlk1QDJizszN NEOxSmlUSU6JRWK=
TCCSUP NXvJWJh7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXPjRZFpUUN3ME2xN{4yOjh2IN88US=> Mlz5V2FPT0WU
SCC-15 NWe0NVJbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWTJR|UxRTF|LkK2OVEh|ryP NXHj[HpEW0GQR1XS
NOS-1 NYPWdpJUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIfweHJKSzVyPUGzMlI5QTNizszN NXvJbXBUW0GQR1XS
RH-1 NI\5PFhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWXJR|UxRTF|LkOwN|ch|ryP MnnIV2FPT0WU
SK-MEL-3 MknhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWTzdm9KUUN3ME2xN{4{PzJ6IN88US=> NVjqNHFJW0GQR1XS
NB5 MmnoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEfFbVZKSzVyPUGzMlQxPjdizszN M4jUUnNCVkeHUh?=
SNU-387 NWnwd|cxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXj3ZY5wUUN3ME2xN{42ODd{IN88US=> NIXn[VVUSU6JRWK=
CAL-120 NHnlT2tIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEP3b5ZKSzVyPUGzMlY4OThizszN M1\RNHNCVkeHUh?=
Mo-T MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYPJR|UxRTF|LkewO{DPxE1? NXO3dm5wW0GQR1XS
LNCaP-Clone-FGC NFTMXlVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoHQTWM2OD1zMz63PVkzKM7:TR?= NH\CS2dUSU6JRWK=
CAN M3nBVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2TzV2lEPTB;MUSuNFI5QCEQvF2= M1S1UnNCVkeHUh?=
SK-MEL-30 M{PtdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVT3dGF7UUN3ME2xOE4xPjNizszN M{LQV3NCVkeHUh?=
COLO-678 M2[3[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnqxTWM2OD1zND6wPFIzKM7:TR?= NF:zS2NUSU6JRWK=
SCC-9 Ml;rS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MV;JR|UxRTF2LkGwNlEh|ryP M2fvZnNCVkeHUh?=
KINGS-1 NHP2NVBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Ml7HTWM2OD1zND6xOFAzKM7:TR?= NEnufYNUSU6JRWK=
SL-513 MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEnG[ItKSzVyPUG0MlE5PyEQvF2= M{XwNXNCVkeHUh?=
HLE MlzNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVvJR|UxRTF2LkO4OVIh|ryP NUPEdmptW0GQR1XS
SW1573 MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWHJR|UxRTF2LkS0N|Uh|ryP M1nNZ3NCVkeHUh?=
KYSE-140 Ml;lS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3nZR2lEPTB;MUSuOlMzPyEQvF2= Mom0V2FPT0WU
SK-PN-DW M1LUbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEnvZ|dKSzVyPUG0MlgxODFizszN MY\TRW5ITVJ?
A253 NEPCOoVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYHLR5ByUUN3ME2xOU4xPjJ3IN88US=> NHvaVGtUSU6JRWK=
CAL-12T M3nQfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUHJR|UxRTF3LkS2OlIh|ryP NUCzfXI3W0GQR1XS
COLO-679 NVPtdGluT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NF7XVmlKSzVyPUG1Mlc3QDNizszN NYrK[mdpW0GQR1XS
UACC-257 NVn1bnd4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NX\nS5RFUUN3ME2xOk4yOjBzIN88US=> NHvRXFZUSU6JRWK=
U-87-MG NY\BdG5mT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVXrXmRLUUN3ME2xOk4{PTJ|IN88US=> MmD6V2FPT0WU
HCC1806 Mm\MS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYTJR|UxRTF4LkewO|Eh|ryP NVrKPJdlW0GQR1XS
NCI-H2170 NGrlVnVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmTlTWM2OD1zNz6yOFQ5KM7:TR?= MVHTRW5ITVJ?
AGS MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWHNU|RrUUN3ME2xO{4{QDB6IN88US=> MVLTRW5ITVJ?
MEL-HO MmKxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlfLTWM2OD1zNz63OVA{KM7:TR?= MYHTRW5ITVJ?
SW48 NX7sSIdUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVXScYNMUUN3ME2xO{44PzF4IN88US=> NV\4PHZrW0GQR1XS
HuP-T4 M4DnfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUDCZVdzUUN3ME2xPE4xOjB4IN88US=> MnPSV2FPT0WU
NCI-H720 MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWr5OohoUUN3ME2xPE4yPDB{IN88US=> NHS2U5RUSU6JRWK=
RCC10RGB NFfkT4tIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NELX[I1KSzVyPUG4MlE3QTdizszN Mnu1V2FPT0WU
HD-MY-Z MmDWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkDJTWM2OD1zOD6yNlU1KM7:TR?= NHPiN5JUSU6JRWK=
A427 MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWPLSVVTUUN3ME2xPE42ODl2IN88US=> M33ydXNCVkeHUh?=
HCC2998 M13kc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NV7YPGtTUUN3ME2xPE43ODVzIN88US=> MkD4V2FPT0WU
EPLC-272H M1PjNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NImzNm9KSzVyPUG5MlA1OzRizszN MX;TRW5ITVJ?
C32 MoLwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXTXWmhkUUN3ME2xPU4xPDVizszN MorWV2FPT0WU
UMC-11 M2PVfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4j4e2lEPTB;MUmuNlEzOyEQvF2= MWrTRW5ITVJ?
CaR-1 NWrjSWpLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NULsSIZLUUN3ME2xPU43QDB2IN88US=> NGfzXoxUSU6JRWK=
KYSE-410 MlLHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnHyTWM2OD1zOT65NVM6KM7:TR?= MlrjV2FPT0WU
HuCCT1 NVmwU|BJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUnJR|UxRTJyLk[yPVQh|ryP NXvGN5hDW0GQR1XS
LB996-RCC M3O2XWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVPJR|UxRTJyLkexOlgh|ryP M2T1OHNCVkeHUh?=
KYSE-70 MnjkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXXacGZvUUN3ME2yNE45ODV7IN88US=> NITTT4pUSU6JRWK=
CAL-72 NEH5NHZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXnLTGFTUUN3ME2yNE46OTVizszN NHHMVYVUSU6JRWK=
Capan-2 MmPFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVfDWIJ2UUN3ME2yNU4xPDF|IN88US=> M4n4UnNCVkeHUh?=
PANC-08-13 NW\IPJduT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVvJR|UxRTJzLkK1NVUh|ryP NWjYcIJrW0GQR1XS
SBC-1 Mn35S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NECxOmxKSzVyPUKxMlMxQDFizszN MmDQV2FPT0WU
MFM-223 MnrGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmHRTWM2OD1{MT6zN|QzKM7:TR?= MojJV2FPT0WU
BB49-HNC NWPGfHU4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NILVOHlKSzVyPUKxMlU4OTZizszN MXvTRW5ITVJ?
SH-4 NYXEUo9IT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MY\JR|UxRTJzLk[2NVgh|ryP M1vBZ3NCVkeHUh?=
HuO9 NUf0T4FET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NULkNGtWUUN3ME2yNU46QDJ3IN88US=> M4PreHNCVkeHUh?=
AM-38 M4DCXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYrE[JBHUUN3ME2yNk4xPDh3IN88US=> NYe1Z5JKW0GQR1XS
A431 MlPDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmTaTWM2OD1{Mz6yNVE6KM7:TR?= M3nLbnNCVkeHUh?=
YAPC NIrhOHFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NU\TS4dkUUN3ME2yN{4zPjVzIN88US=> MVvTRW5ITVJ?
LU-139 NIDIRZhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlfXTWM2OD1{Mz60PFA6KM7:TR?= NU\Ke3NYW0GQR1XS
HEC-1 NE[3XndIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NH;Qd|VKSzVyPUKzMlQ6OzdizszN M4jRXXNCVkeHUh?=
SCC-25 MnO0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFHnRlNKSzVyPUK0MlMxODZizszN NVO5bW1{W0GQR1XS
HT-29 NYDse2xjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NET0coZKSzVyPUK0MlM5OjNizszN MkLOV2FPT0WU
PC-14 MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFjEXpVKSzVyPUK0MlY2PzFizszN NUD0dJJFW0GQR1XS
Calu-6 NWLLe5hwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M13sTmlEPTB;MkWuOVA4OSEQvF2= NI[4fJJUSU6JRWK=
SJRH30 NFTrT4xIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NX7wNFM{UUN3ME2yOU43PDl4IN88US=> MkDMV2FPT0WU
ChaGo-K-1 MlzLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUfJR|UxRTJ4LkG2Nlkh|ryP NUj0e2RwW0GQR1XS
IA-LM M3PRbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnTtTWM2OD1{Nj6zOlQ2KM7:TR?= MYXTRW5ITVJ?
GP5d M1G2SGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFfQcJpKSzVyPUK2MlQ1QTFizszN NXPqVWtJW0GQR1XS
NCI-H2291 NIDhPHBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHTlR4RKSzVyPUK2MlY2PDFizszN NWTFcYRrW0GQR1XS
BALL-1 M1XHVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWLJR|UxRTJ4LkmzPVch|ryP NV;IOXR2W0GQR1XS
HCC1954 Mn3SS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmXLTWM2OD1{Nj65PFA5KM7:TR?= NYXIbnd3W0GQR1XS
NCI-H2452 MoXhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGDme2xKSzVyPUK3MlQyPjNizszN M2PYSHNCVkeHUh?=
LU-99A M3j2R2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2K1TGlEPTB;MkeuOVU5OiEQvF2= M1XwVnNCVkeHUh?=
NTERA-S-cl-D1 M3roU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVXJR|UxRTJ5LkeyPVkh|ryP M2HxXXNCVkeHUh?=
PANC-10-05 M3vEN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MU\JR|UxRTJ5Lke3O|Uh|ryP MnHRV2FPT0WU
NCI-H2405 MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEnvWI5KSzVyPUK3Mlk{QDdizszN MofXV2FPT0WU
MDA-MB-415 NV75OmhFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoPDTWM2OD1{OD60NVM4KM7:TR?= M2DJOnNCVkeHUh?=
NCI-H2342 M3q4O2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVnW[HliUUN3ME2yPE42OjhzIN88US=> MXLTRW5ITVJ?
TGBC24TKB MmDTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MV3JR|UxRTJ6LkexNVch|ryP MlTMV2FPT0WU
LU-134-A NHGwc|ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnzkTWM2OD1{OD65NlYyKM7:TR?= MYrTRW5ITVJ?
SCC-4 NH:4b49Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4n0TGlEPTB;M{GuNFQ6PCEQvF2= NV35XpFOW0GQR1XS
Saos-2 MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYLJR|UxRTNzLkmzNFYh|ryP MYPTRW5ITVJ?
RERF-LC-MS M{Dud2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYfJR|UxRTN{LkiyN|Eh|ryP MXvTRW5ITVJ?
M14 MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVS4O4NtUUN3ME2zNk46PzZ2IN88US=> NV7sW|JuW0GQR1XS
HPAF-II MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUTJR|UxRTN|LkWwNVEh|ryP NX;rcHhMW0GQR1XS
NCI-H1755 NWPyZ|NOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NV;HW3hGUUN3ME2zOE4{OzB3IN88US=> NHS0RolUSU6JRWK=
D-392MG NW\SZlMyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEfoNFRKSzVyPUO1Mlg3PzRizszN MUjTRW5ITVJ?
A704 MlrnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYjJR|UxRTN4LkC0Nlch|ryP NVjTdVNpW0GQR1XS
CP50-MEL-B M2Pu[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHy3TXVKSzVyPUO2MlE6OTFizszN M33FXnNCVkeHUh?=
EW-18 MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGL6VGhKSzVyPUO2MlQ2OiEQvF2= Ml7DV2FPT0WU
WM-115 NXP0[JVyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHrWU3lKSzVyPUO2MlgxQTlizszN NXTKVJlHW0GQR1XS
LU-65 MnHYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3\LcWlEPTB;M{euNVQyPyEQvF2= NFjiTW9USU6JRWK=
NCI-H1563 NU\ucoR1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVvyVYlxUUN3ME2zO{4zPDh2IN88US=> M3jqVnNCVkeHUh?=
DBTRG-05MG MkDES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{TmTGlEPTB;M{iuNFY6OSEQvF2= MUfTRW5ITVJ?
NCI-H630 Mk\lS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVXJR|UxRTN6LkS3NVQh|ryP M4nDeHNCVkeHUh?=
NCI-H1155 M4DXRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFv5RlBKSzVyPUO5MlI1OiEQvF2= MV7TRW5ITVJ?
OVACR-3 NX7Hc|BGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGroT2pKSzVyPUO5MlkyQTVizszN NUTPXo5lW0GQR1XS
OAW-42 M{LDUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmPxTWM2OD12MD60NlU5KM7:TR?= NVvVW291W0GQR1XS
JVM-2 M2WxPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NX3lTGJUUUN3ME20NU4zPDF3IN88US=> Mnu3V2FPT0WU
C3A M3PubWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVPJR|UxRTRzLkO0OFch|ryP MUfTRW5ITVJ?
HT55 MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUjJR|UxRTR{LkK4OFEh|ryP NHLjWZRUSU6JRWK=
OVCAR-4 M3HVSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NE\YfGVKSzVyPUSyMlI6PzRizszN NVTjbZMzW0GQR1XS
MEG-01 MoHqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFzlWoxKSzVyPUSyMlQ3OTZizszN NFywZ|VUSU6JRWK=
NCI-H82 NEfPRopIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mon1TWM2OD12Mz65PFkzKM7:TR?= M3m3T3NCVkeHUh?=
JEG-3 NYj2O4dMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFz1dmpKSzVyPUS0Mlk1PyEQvF2= M{P5UHNCVkeHUh?=
BPH-1 NED1W2VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mmn1TWM2OD12Nj6zPVk5KM7:TR?= MVjTRW5ITVJ?
MPP-89 MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWXJR|UxRTR5LkK4PVgh|ryP Ml7CV2FPT0WU
ALL-PO M1jRV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUXJR|UxRTR5LkSxPFgh|ryP MVjTRW5ITVJ?
HT MkfQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1zYd2lEPTB;NEeuOFkzKM7:TR?= Mmf6V2FPT0WU
NCI-H2347 NFLiPWJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mof3TWM2OD12OD6wO|E2KM7:TR?= MVPTRW5ITVJ?
A2780 MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWTZUWtkUUN3ME20PU41OjJ6IN88US=> NV;yTYxNW0GQR1XS
KARPAS-299 NVvvVY1zT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYTIU2IxUUN3ME20PU42OTF7IN88US=> M4\zOHNCVkeHUh?=
NCI-H1651 NH;ke2pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlviTWM2OD12OT64PFIyKM7:TR?= NFHqR2tUSU6JRWK=

... Click to View More Cell Line Experimental Data

Assay
Methods Test Index PMID
Western blot
RB1 (pT821) / RB1 (pS780) / RB1 / CDK6 / CCND2 / RUNX1 / ETO; 

PubMed: 30300583     


Immunoblots showing dose-dependent impact of 72 hr palbociclib treatment on indicated protein levels in Kasumi-1 and SKNO-1 cells.

pRb(S807, 811) / CDK4 / CDK6 / PARP; 

PubMed: 28453226     


Effects of palbociclib on CDK4/6-Rb pathway. HCC cells were treated with different doses of palbociclib for 24 h, and then, the cells were subjected to western blot analysis. CF, cleaved fragment. 

LC3-I / LC3-II; 

PubMed: 28453226     


Palbociclib increases LC3-II amount in a dose-dependent manner in HCC cell lines. 

pAMPKα(T172) / pULK1(S317); 

PubMed: 28453226     


Dose-dependent response of palbociclib on AMPK-related molecules. HCC cells were treated with different concentrations of palbociclib for 24 h. The phosphorylation of the indicated proteins was determined by western blotting. 

SMAD2 (pS255); 

PubMed: 30343527     


T47D cells were treated with indicated concentrations of palbociclib for 24 h to evaluate substrate phosphorylation.

30300583 28453226 30343527
Growth inhibition assay
Cell viability; 

PubMed: 29670090     


Cell viability was determined by MTT assays after palbociclib exposure for 2, 4, and 6 days. The cell cycle of SYO-1 and Fuji cells was assessed after exposure to palbociclib (1 µM) for 24 h by flow cytometry analysis.

29670090
Immunofluorescence
SAHF/ATRX; 

PubMed: 26988987     


DAPI staining for senescence-associated heterochromatic foci (SAHF, left panel) and ATRX staining (right panel) in 1205Lu cells +/− palbociclib for 8 days. 

LC3B; 

PubMed: 28453226     


LC3B immunofluorescence in palbociclib‐treated Hep3B cells. Arrowheads indicate LC3-positive autophagosomes. Nuclei were counterstained with DAPI (blue).

26988987 28453226
ELISA
PGE2; 

PubMed: 26540629     


The supernatant of control and 7.5 μM palbociclib-treated cells was collected and stored at −80°C. PGE2 secretion was detected using ELISA.

26540629
In vivo PD 0332991 indicates complete tumor stasis in a MDA-MB-435 xenograft at 150 mg/kg. PD 0332991 also shows broad-spectrum antitumor activity in multiple human tumor xenografts by eliminating phospho-Rb and the proliferative marker Ki-67 from tumor tissue and down-regulation of genes under the transcriptional control of E2F. [1]

Protocol

Kinase Assay:

[1]

- Collapse

Cdk Assays:

A stock solution of PD0332991 is prepared in DMSO. CDK assays are performed in 96-well filter plates. All CDK-cyclin kinase complexes are expressed in insect cells through baculovirus infection and purified. The substrate for the assays is a fragment (amino acids 792–928) of pRb fused to GST (GST·RB-Cterm). The total volume in each well is 0.1 mL containing a final concentration of 20 mM Tris-HCl, pH 7.4, 50 mM NaCl, 1 mM dithiothreitol, 10 mM MgCl2, 25 μM ATP (for CDK4-cyclin D1, CDK6-cyclin D2, and CDK6-cyclin D3) or 12 μM ATP (for CDK2-cyclin E, CDK2-cyclin A, and CDC2-cyclin B) containing 0.25 μCi of [γ-32P]ATP, 20 ng of enzyme, 1 μg of GST·RB-Cterm, and PD 0332991 (0.001-0.1μM). All components except the [γ-32P]ATP are added to the wells, and the plate is placed on a plate mixer for 2 min. The reaction is started by adding the [γ-32P]ATP and the plate is incubated at 25 °C for 15 min. The reaction is terminated by addition of 0.1 mL of 20% trichloroacetic acid and the plate is kept at 4  °C for at least 1 hour to allow the substrate to precipitate. The wells are then washed 5 times with 0.2 mL of 10% trichloroacetic acid and radioactive incorporation is determined with a β plate counter.
Cell Research:

[1]

- Collapse
  • Cell lines: Tumor cell lines including MDA-MB-435, ZR-75-1, T-47D, MCF-7, H1299, Colo-205, MDA-MB-468, H2009, CRRF-CEM and K562
  • Concentrations: 0.01-1 μM
  • Incubation Time: 24 hours
  • Method:

    Cells are seeded at 2 × 104 per well in a 96-well plate and incubated overnight. PD 0332991 (0.01-1 μM) is added to the wells and incubated at 37 °C for another 24 hours. [14C]Thymidine (0.1 μCi) is added to each well and incorporation of the radiolabel is allowed to proceed for 72 hours. Incorporated radioactivity is determined with a β plate counter.


    (Only for Reference)
Animal Research:

[1]

- Collapse
  • Animal Models: Advanced stage human tumor xenografts including Colo-205, MDA-MB-435 breast, SF-295 glioblastoma, ZR-75-1 breast, PC-3 prostate, H125 lung, SW-620 colon, H23 lung and MDA-MB-468 breast (Rb negative) are established in severe combined immunodeficient mice.
  • Dosages: 0-150 mg/kg
  • Administration: Given by gavage
    (Only for Reference)

Solubility (25°C)

In vitro Water 30 mg/mL (61.98 mM)
DMSO 3 mg/mL warmed (6.19 mM)
Ethanol Insoluble
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
Saline
For best results, use promptly after mixing.
6 mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 483.99
Formula

C24H29N7O2.HCl

CAS No. 827022-32-2
Storage powder
in solvent
Synonyms N/A
Smiles CC1=C(C(=O)N(C2=NC(=NC=C12)NC3=NC=C(C=C3)N4CCNCC4)C5CCCC5)C(=O)C.Cl

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
Dosage mg/kg Average weight of animals g Dosing volume per animal ul Number of animals
Step 2: Enter the in vivo formulation ()
% DMSO % % Tween 80 % ddH2O
CalculateReset

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment interventions Conditions Sponsor/Collaborators Start Date Phases
NCT04483505 Not yet recruiting Drug: Combination Rogaratinib + palbociclib + fulvestrant Breast Cancer Metastatic|Hormone Receptor Positive Malignant Neoplasm of Breast Fundacion CRIS de Investigación para Vencer el Cáncer|Bayer|Pfizer|Apices Soluciones S.L. October 1 2020 Phase 1
NCT04360941 Recruiting Drug: Palbociclib|Drug: Avelumab Triple Negative Breast Cancer|Locally Advanced Breast Cancer|Recurrent Breast Cancer|Metastatic Breast Cancer|ER+ Breast Cancer|HER2-positive Breast Cancer Royal Marsden NHS Foundation Trust|Pfizer|Breast Cancer Now August 11 2020 Phase 1
NCT03870919 Suspended Drug: Palbociclib|Other: locoregional treatment Breast Cancer Stage IV|Radiotherapy|Surgery UNICANCER|Pfizer October 23 2019 Not Applicable

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

CDK Signaling Pathway Map

CDK Inhibitors with Unique Features

Related CDK Products

Tags: buy Palbociclib|Palbociclib ic50|Palbociclib price|Palbociclib cost|Palbociclib solubility dmso|Palbociclib purchase|Palbociclib manufacturer|Palbociclib research buy|Palbociclib order|Palbociclib mouse|Palbociclib chemical structure|Palbociclib mw|Palbociclib molecular weight|Palbociclib datasheet|Palbociclib supplier|Palbociclib in vitro|Palbociclib cell line|Palbociclib concentration|Palbociclib nmr|Palbociclib in vivo|Palbociclib clinical trial|Palbociclib inhibitor|Palbociclib Cell Cycle inhibitor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID